Nanogen to Release Third Quarter Financial Results and Host Webcast on Wednesday, November 3, 2004

Oct 26, 2004, 01:00 ET from Nanogen, Inc.

    SAN DIEGO, Oct. 26 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq:   NGEN)
 will host a conference call on Wednesday, November 3, 2004 at 4:30 p.m.
 Eastern (1:30 p.m. Pacific) to discuss 2004 third quarter financial results.
 The financial results press release will be issued at close of market on
 November 3rd.
     Audio of management's presentation will be available via live webcast on
 the investor relations section of Nanogen's corporate website at, and will be archived for 90 days.  A digital recording of the
 call will also be available for 48 hours, beginning two hours after the
 completion of the conference call on November 3, and can be accessed via
 telephone at (877) 519-4471 for US/Canada participants, and (973) 341-3080 for
 international participants.  The conference ID, 5299122, will be required to
 listen to the playback.
     About Nanogen, Inc.
     Nanogen develops advanced in vitro diagnostics to provide physicians and
 patients worldwide with sophisticated information to predict, diagnose and
 treat disease.  Research and clinical reference labs use the highly accurate
 and reliable NanoChip(R) Molecular Biology Workstation and NanoChip(R)
 Electronic Microarray to develop tests to detect genetic mutations associated
 with a variety of diseases, such as cystic fibrosis, Alzheimer's and
 cardiovascular disease.  Nanogen's subsidiary SynX offers a line of
 point-of-care antibody-based diagnostic tests and is building expertise in
 cardiac related health conditions.  Nanogen's ten years of pioneering research
 involving nanotechnology may also have future applications in medical
 diagnostics, biowarfare and other industries.  For additional information
 please visit Nanogen's website at
     Forward-Looking Statement
     This press release contains forward-looking statements that are subject to
 risks and uncertainties that could cause actual results to differ materially
 from those set forth in the forward-looking statements, including whether
 patents owned or licensed by Nanogen will be developed into products, whether
 the patents owned by Nanogen offer any protection against competitors with
 competing technologies, whether Nanogen's NanoChip(R) System can be
 successfully further commercialized, whether other products under development
 can be successfully developed and commercialized, whether results reported by
 our customers or partners can be identically replicated, whether ASRs
 currently sold by Nanogen will become FDA-approved molecular diagnostic test
 kits, whether Nanogen will be successful in developing additional ASRs and
 protocols utilizing the NanoChip(R) System, and other risks and uncertainties
 discussed under the caption "Factors That May Affect Results" and elsewhere in
 Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and
 Exchange Commission.  These forward-looking statements speak only as of the
 date hereof.  Nanogen disclaims any intent or obligation to update these
 forward-looking statements.

SOURCE Nanogen, Inc.